The field of respiratory pharmacology & therapeutics is undergoing rapid transformation through precision medicine, novel delivery platforms, and molecular innovation. The development of dual and triple inhaler combinations, biologics targeting eosinophilic inflammation, and kinase inhibitors for fibrotic lung diseases is changing clinical paradigms. Drug response heterogeneity is now being addressed using pharmacogenomic profiling and phenotype-based treatment algorithms. Respiratory Pharmacology & Therapeutics also encompasses advances in aerosol science, including smart inhaler devices with dose tracking and feedback systems to improve adherence. As new therapeutic targets are identified through omics-based research, regulatory bodies are adapting frameworks to support accelerated approval pathways. Inhalation toxicology and drug-device compatibility are emerging concerns as personalized therapies become more complex. A collaborative ecosystem between pharmacologists, respiratory clinicians, and biotech innovators is vital to translate discovery into effective, patient-centric care.